( NASDAQ-SMALL:IMNP )

News from Immune Pharmaceuticals Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

20 Jun, 2017, 09:14 ET Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML)

Immune Pharmaceuticals (NASDAQ:IMNP) ("Immune"), a clinical stage biopharmaceutical company, announced today that patient enrollment in a Phase...


19 Jun, 2017, 08:30 ET Immune Receives NASDAQ Compliance Letter

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company") announced today that on June 15, 2017, the Company received written notice from the...


15 Jun, 2017, 09:28 ET Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ('Immune') announced today that it has signed an agreement with Meda, a Mylan NV company ('Mylan') to...


26 May, 2017, 08:30 ET Immune Receives Nasdaq Letters

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company") announced today that on May 24, 2017, the Company received written notice from Nasdaq...


04 May, 2017, 09:00 ET Immune Pharmaceuticals Announces Private Placement of up to $3.4 Million

Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune" or the "Company") today announced that it has entered into definitive agreements with several...


20 Apr, 2017, 08:00 ET Immune Pharmaceuticals Signs Letter of Intent with Pint Pharma Regarding License and Commercializion of Ceplene® in Latin America

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or "Immune Pharma") announced today that it has entered into a letter of intent with Pint...


13 Mar, 2017, 09:55 ET Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement

Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune" or the "Company"), announced today that following a hearing on March 9, 2017, where the...


28 Feb, 2017, 08:30 ET Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid

Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune" or the "Company") today announced that it has broadened enrollment eligibility criteria based...


17 Feb, 2017, 09:15 ET Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia

Immune Pharmaceuticals Inc. (Nasdaq: IMNP), will announce on Monday, February 20th, 2017 at the Acute Leukemia XVI symposium in Munich, Germany...


27 Jan, 2017, 07:00 ET Immune Pharmaceuticals Appoints New Chairman of the Board of Directors

Immune Pharmaceuticals Inc. (Nasdaq: IMNP), announced today it has appointed Ranch C. Kimball, a highly regarded executive in healthcare,...


23 Jan, 2017, 08:45 ET Immune Pharmaceuticals Enters a Research Partnership to Develop Mono- and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment

Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company developing novel therapeutics for the...


17 Jan, 2017, 09:10 ET Immune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI

Immune Pharmaceuticals (NASDAQ: IMNP) ("Immune"), a clinical stage biopharmaceutical company, announced today that it will hold a Satellite...


09 Jan, 2017, 18:11 ET Immune Pharmaceuticals Will Request an Appeal to Regain Compliance with Nasdaq's Minimum Bid Price Rule

Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune"), announced today that it intends to request a hearing before the Nasdaq Listing...


22 Nov, 2016, 09:00 ET Immune Pharmaceuticals Announces Immuno-Oncology R&D Update on December 8, 2016

Immune Pharmaceuticals (NASDAQ: IMNP) (Immune) announced today that it will hold an Immuno-Oncology R&D Update for investors on December 8,...


17 Nov, 2016, 09:15 ET Immune Pharmaceuticals Secures Up to $11 Million in New Financing to be Deployed With a Focus on Bertilimumab Clinical Development

Immune Pharmaceuticals (NASDAQ:IMNP) (Immune) announced today that it has secured up to $11 million in new financing from a single family office...


27 Oct, 2016, 07:00 ET Immune Pharmaceuticals Receives FDA Guidance for Phase III Pivotal Trial of its AML Therapy Ceplene® In Combination with Low Dose IL-2

Immune Pharmaceuticals (NASDAQ:IMNP) (Immune) announced today that it has received guidance from the United States Food and Drug Administration...


17 Oct, 2016, 09:23 ET Immune Pharmaceuticals Announces Formation of Management Team for Maxim Pharmaceuticals, its Pain and Neurology Subsidiary

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced today that it has entered into a consulting agreement with Joseph V. Pergolizzi...


16 Sep, 2016, 07:30 ET Immune Pharmaceuticals Signs Agreement to Fund Maxim Pharmaceuticals, Inc., its Pain and Neurology subsidiary

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company"), a biopharmaceutical company focused on the development of targeted...


07 Sep, 2016, 07:30 ET Immune Pharmaceuticals Receives $2 Million Investment in Common Stock at $0.50 per Share

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune"), a biopharmaceutical company focused on the development of targeted therapeutics for the...


16 Aug, 2016, 07:30 ET Immune Pharmaceuticals Provides Business and R&D Update and Announces Second Quarter 2016 Financial Results

 Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune" or the "Company") announced financial results for the second quarter and six months ended...


19 Jul, 2016, 09:30 ET IMMUNE Pharmaceuticals to Form Pain and Neurology Spin Off Company around AmiKet

Immune Pharmaceuticals Inc. (NASDAQ: IMNP)("Immune"), a biopharmaceutical company focused on the development of targeted therapeutics for the...


28 Jun, 2016, 07:00 ET New Data Suggests Improved Tumor Response For The Combination of AZIXA® and Immune Checkpoint Inhibitors in The Treatment of Cancer

 Immune Pharmaceuticals Inc. ("Immune" or the "Company") (NASDAQ: IMNP), a clinical-stage biopharmaceutical company announced today that recent...


20 Jun, 2016, 17:30 ET New Data shows that Ceplene® Enhances Response to anti PD-1 and anti-PD-L1 Immune Checkpoint Inhibitors in Lymphoma and Solid Tumor Models

 Immune Pharmaceuticals (NASDAQ:IMNP),("Immune"),  a clinical stage biopharmaceutical company announced that  scientists from...


20 Jun, 2016, 08:06 ET Immune Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company announced today that Dr. Daniel Teper,...


14 Jun, 2016, 07:30 ET Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune"), a biopharmaceutical company focused on the development of targeted therapeutics for the...